# Immunogenicity and Safety of BoostrixTM Using a New Syringe in 10 to 15-year Old Adolescents

> **NCT01362322** · PHASE4 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 671 (actual)

## Conditions studied

- Diphtheria
- Tetanus
- Acellular Pertussis

## Interventions

- **BIOLOGICAL:** Boostrix TM (new syringe presentation)
- **BIOLOGICAL:** Boostrix TM (previous syringe presentation)

## Key facts

- **NCT ID:** NCT01362322
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-07-01
- **Primary completion:** 2012-09-03
- **Final completion:** 2012-09-03
- **Target enrollment:** 671 (ACTUAL)
- **Last updated:** 2018-08-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01362322

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01362322, "Immunogenicity and Safety of BoostrixTM Using a New Syringe in 10 to 15-year Old Adolescents". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01362322. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*